Bicycle Therapeutics plc (BCYC)
BCYC Stock Price Chart
Explore Bicycle Therapeutics plc interactive price chart. Choose custom timeframes to analyze BCYC price movements and trends.
BCYC Company Profile
Discover essential business fundamentals and corporate details for Bicycle Therapeutics plc (BCYC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 May 2019
Employees
305.00
CEO
Kevin Lee
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
BCYC Financial Timeline
Browse a chronological timeline of Bicycle Therapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$1.05.
Earnings released on 8 Aug 2025
EPS came in at -$1.14 falling short of the estimated -$0.95 by -20.00%, while revenue for the quarter reached $2.92M , missing expectations by -65.16%.
Earnings released on 1 May 2025
EPS came in at -$0.88 falling short of the estimated -$0.86 by -2.33%, while revenue for the quarter reached $9.98M , beating expectations by +8.01%.
Earnings released on 25 Feb 2025
EPS came in at -$0.80 surpassing the estimated -$0.85 by +5.88%, while revenue for the quarter reached $3.71M , missing expectations by -48.94%.
Earnings released on 31 Oct 2024
EPS came in at -$0.74 surpassing the estimated -$0.78 by +5.13%, while revenue for the quarter reached $2.68M , missing expectations by -56.87%.
Earnings released on 6 Aug 2024
EPS came in at -$0.77 surpassing the estimated -$1.10 by +30.00%, while revenue for the quarter reached $9.37M , beating expectations by +51.89%.
Earnings released on 2 May 2024
EPS came in at -$0.62 surpassing the estimated -$1.26 by +50.79%, while revenue for the quarter reached $19.52M , beating expectations by +223.70%.
Earnings released on 20 Feb 2024
EPS came in at -$1.16 surpassing the estimated -$1.23 by +5.69%, while revenue for the quarter reached $5.33M , missing expectations by -25.34%.
Earnings released on 2 Nov 2023
EPS came in at -$1.26 falling short of the estimated -$1.06 by -18.87%, while revenue for the quarter reached $5.35M , missing expectations by -19.40%.
Earnings released on 3 Aug 2023
EPS came in at -$1.41 falling short of the estimated -$1.10 by -28.18%, while revenue for the quarter reached $11.40M , beating expectations by +148.84%.
Earnings released on 4 May 2023
EPS came in at -$1.30 falling short of the estimated -$1.06 by -22.64%, while revenue for the quarter reached $4.90M , beating expectations by +26.19%.
Earnings released on 28 Feb 2023
EPS came in at -$1.01 surpassing the estimated -$1.06 by +4.72%, while revenue for the quarter reached $3.19M , missing expectations by -10.35%.
Earnings released on 3 Nov 2022
EPS came in at -$0.96 surpassing the estimated -$0.98 by +2.04%, while revenue for the quarter reached $3.04M , missing expectations by -46.70%.
Earnings released on 4 Aug 2022
EPS came in at -$0.90 falling short of the estimated -$0.82 by -9.76%, while revenue for the quarter reached $4.38M , beating expectations by +18.70%.
Earnings released on 5 May 2022
EPS came in at -$0.93 falling short of the estimated -$0.70 by -32.86%, while revenue for the quarter reached $3.86M , missing expectations by -13.54%.
Earnings released on 1 Mar 2022
EPS came in at -$0.63 falling short of the estimated -$0.60 by -5.00%, while revenue for the quarter reached $3.77M , missing expectations by -31.73%.
Earnings released on 4 Nov 2021
EPS came in at -$0.59 surpassing the estimated -$0.67 by +11.94%, while revenue for the quarter reached $4.33M , missing expectations by -6.01%.
Earnings released on 5 Aug 2021
EPS came in at -$0.74 falling short of the estimated -$0.72 by -2.78%, while revenue for the quarter reached $1.79M , missing expectations by -22.73%.
Earnings released on 6 May 2021
EPS came in at -$0.73 falling short of the estimated -$0.66 by -10.61%, while revenue for the quarter reached $1.81M , beating expectations by +2.90%.
Earnings released on 11 Mar 2021
EPS came in at -$0.83 falling short of the estimated -$0.50 by -66.00%, while revenue for the quarter reached $3.85M .
Earnings released on 5 Nov 2020
EPS came in at -$0.52 surpassing the estimated -$0.66 by +21.21%, while revenue for the quarter reached $3.84M , beating expectations by +236.43%.
BCYC Stock Performance
Access detailed BCYC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.